Protagonist Therapeutics Inc (PTGX)
Return on total capital
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | — | -93,652 | -131,373 | -125,845 | -64,451 |
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 675,295 | 336,677 | -536,755 | -409,362 | -283,811 |
| Return on total capital | 0.00% | -27.82% | — | — | — |
December 31, 2024 calculation
Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $675,295K)
= 0.00%
Protagonist Therapeutics Inc had a negative return on total capital of -27.82% as of December 31, 2023, indicating that the company's investments and operations did not generate returns sufficient to cover its total capital employed during that period. The following year, as of December 31, 2024, the return on total capital improved to 0.00%, suggesting that the company managed to achieve a breakeven point where its returns matched the total capital invested. It is important for the company to monitor and improve its return on total capital to ensure long-term financial sustainability and profitability. Further analysis and comparison with industry benchmarks would provide more insights into the company's financial performance and efficiency in utilizing its capital resources.
Peer comparison
Dec 31, 2024